Gene Therapy
🇪🇺 EMA Page 2EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Unlock global gene therapy market insights. Stay ahead on regulatory approvals, clinical trials, and investment opportunities in this cutting-edge biotech sector.
Showing 13–24 of 26 articles
Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment
BioPharma Clinical Trials: Gene Therapy, Obesity, and Oncology Updates
EMA Issues Positive Opinion for Itvisma (Onasemnogene Abeparvovec) Gene Therapy for Spinal Muscular Atrophy
RNA Therapy Clinical Trials Market Reaches $3.4 Billion as Personalized Medicine Drives Growth Through 2035
Center for Cancer and Blood Disorders Launches CAR T-Cell Therapy Program in Maryland, Expanding Community Access
ISCT 2026: Cell & Gene Therapy Manufacturing Innovations in Dublin
Allogene Therapeutics Expands Cemacabtagene Ansegedleucel Phase 2 ALPHA3 Trial to South Korea and Australia
AskBio's Ametefgene Parvec Enters Phase II Trial for Parkinson's Disease Gene Therapy
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
Gene Therapy Market to Reach $43.8 Billion by 2034 as CRISPR and AAV Technologies Drive 12.27% Annual Growth